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Abstract
 
Maturational changes at the CD4
 
2
 
CD8
 
2
 
 
 
double negative (DN) to CD4
 
1
 
CD8
 
1
 
 double posi-
tive (DP) transition are dependent on signals generated via the pre–T cell receptor (TCR) and
the nonreceptor protein tyrosine kinase p56
 
lck
 
 (Lck). How Lck activities are stimulated or re-
layed after pre-TCR formation remains obscure. Our structure–function mapping of Lck thy-
mopoietic properties reveals that the noncatalytic domains of Lck are specialized to signal effi-
cient cellular expansion at DN to DP transition. Moreover, although substitution of the Lck
catalytic domain with FynT sequences minimally impacts DP development, single positive thy-
mocytes are most efficiently produced in the presence of kinases containing both the NH
 
2
 
-ter-
minal and catalytic regions of Lck. These findings demonstrate that the Lck structure is
uniquely adapted to mediate signals at both major transitions in thymopoiesis.
Key words: thymus • signal transduction • cellular differentiation • protein kinases • 
lymphocytes
 
Introduction
 
T cell development begins when bone marrow–derived
precursors seed the thymus, where they expand and differ-
entiate into mature T cells (for a review, see reference 1).
When examined by flow cytometry, the most immature
cells of the 
 
a
 
/
 
b
 
 lineage lack expression of both CD4 and
CD8 coreceptors (CD4
 
2
 
CD8
 
2
 
 double negative [DN]
 
1
 
thymocytes). Recombination activating gene (Rag)-depen-
dent rearrangements at the TCR-
 
b
 
 locus are initiated in a
subset of these DN cells (CD44
 
1
 
CD25
 
2
 
), and the TCR 
 
b
 
chains subsequently produced are expressed in CD44
 
2
 
CD25
 
1
 
 intermediates in the form of a pre-TCR that con-
sists of TCR-
 
b
 
, the nonpolymorphic pre-T
 
a
 
 chain, the
CD3 complex, and associated 
 
z
 
 chains (for a review, see
reference 2). Pre-TCR expression is required to promote
transition of thymocytes from DN progenitors to CD4
 
1
 
CD8
 
1
 
 double positive (DP) intermediates through a pro-
cess marked by dramatic proliferative expansion and nu-
merous differentiative changes (downregulation of CD25,
synthesis of CD4 and CD8 coreceptors, and allelic exclu-
sion at TCR-
 
b
 
). Subsequent DNA rearrangements at the
TCR-
 
a
 
 locus in DP cells permit assembly of TCR-
 
a
 
/
 
b
 
,
which is required to mediate the transition from DP inter-
mediates to mature CD4 or CD8 single positive (SP) cells.
Thus, both transitions (DN to DP and DP to SP) rely on
the ability of a TCR structure to trigger transmembrane
signals, and on the ability of these signals to engage specific
developmental programs.
Several lines of evidence suggest that the Src family non-
receptor protein tyrosine kinase (PTK) p56
 
lck
 
 (Lck) func-
tions as a key downstream regulator of pre-TCR signals.
DP thymocyte development is severely compromised
when Lck expression or activity is diminished during thy-
mopoiesis (3, 4). Similarly, transgenic TCR-
 
b
 
 expression
fails to enforce allelic exclusion at the endogenous TCR-
 
b
 
locus in the absence of Lck (5, 6). Parallel studies demon-
strated that Lck and TCR-
 
b
 
 transgenes produce similar in
vivo effects, such as inhibiting V
 
b
 
-D
 
b
 
 rearrangement and
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rescuing DP development in Rag
 
2
 
/
 
2
 
 mice (7, 8). Taken
together, these observations support a model in which Lck
transduces pre-TCR signals that regulate differentiation,
proliferative expansion, and allelic exclusion at DN to DP
transition (9). These Lck-dependent signals appear to be re-
layed in part through kinases of the Syk/ZAP-70 family
(10, 11), the Src homology (SH)2 domain–containing leu-
kocyte protein of 76 kD (SLP-76) adaptor (12, 13), the
guanosine triphosphatase Rho (14), and via components of
the Ras/Raf/mitogen-activated protein kinase pathway
(15–17).
Although other Src PTK family members (Src-PTKs)
are expressed in thymocytes, a variety of studies have sug-
gested that Lck is distinctive in its ability to influence early
thymocyte development. FynT, the hematopoietic isoform
of p59
 
fyn
 
, is also detectable in thymocytes and mature T
cells (18, 19). However, unlike Lck, loss of Fyn activity
does not compromise early thymocyte development
 
 
 
(20,
21). In transgenic experiments, augmented FynT expres-
sion also failed to reproduce phenotypes associated with
Lck overexpression, leaving thymocyte cellularity un-
changed and subset representation intact (18, 22). These
findings suggested that, although highly related, FynT and
Lck do not behave identically in the same cellular context.
Thymic expression of a third closely related Src-PTK had
no effect on the maturation or activation characteristics of
transgenic thymocytes (23). Thus, Lck appears to possess
specialized thymopoietic properties that cannot be readily
duplicated by other Src-PTKs. The findings that endoge-
nous FynT cannot fully compensate for loss of Lck func-
tion at DN to DP transition (24, 25), and that transgenic
overexpression of activated mutant FynT only partially res-
cues thymopoiesis in the Lck
 
2
 
/
 
2
 
 strain (25), further support
the view that these two related enzymes possess both
unique and overlapping functional characteristics in vivo.
Src-PTKs share a common domain structure consisting
of a highly conserved catalytic or SH1 domain and several
noncatalytic domains, including an NH
 
2
 
-terminal consen-
sus sequence for myristylation, a distinctive NH
 
2
 
-terminal
unique region, SH3 and SH2 domains that bind proline-
rich sequences and phosphotyrosine-containing peptide se-
quences, respectively, and a short COOH-terminal tail
containing the major regulatory tyrosine residue (for a re-
view, see reference 26). In principle, functional specializa-
tion of Src-PTKs could reflect differences in any of these
Src-PTK domains, and each region has been reported to
specify distinctive protein–protein interactions. Associa-
tions between Lck and the CD4/CD8 coreceptors and be-
tween Fyn and the CD3 complex are dictated by specific
motifs residing in the Src-PTK unique region (27–29).
Similarly, SH2 and SH3 regions of different Src-PTKs bind
discrete sets of proteins, conferring distinct signaling char-
acteristics to the individual enzymes (30–32). Moreover,
recent studies suggest that some level of substrate selectivity
may be imparted by unique sequences in the PTK catalytic
domain (33).
The Lck CD4 or CD8 interactive motif appears to be
dispensable for Lck function at DN to DP transition (4, 8).
In addition, although mutant forms of Lck lacking kinase
activity can enhance TCR signaling in some circumstances
(34), catalytic activity is an essential component of Lck
function at DN to DP transition (4). Aside from the re-
quirement for an active catalytic domain, the PTK struc-
tural features that impact Lck signal initiation or relay at
DN to DP transition remain undefined. As analysis of chi-
meric Src-PTKs has proven to be a powerful strategy for
assaying the contribution of Src-PTK domains to kinase
functions in vitro, we have adopted this approach in an ef-
fort to define regions of Lck structure that are required to
efficiently mediate developmental transitions in vivo. Our
initial analysis has focused on examining the contribution
of regulatory versus catalytic regions to Lck thymopoietic
functions. This was accomplished by exchanging catalytic
domains between Lck and Fyn, and by subsequently defin-
ing the ability of these altered Src-PTKs to support thy-
mopoiesis in animals lacking endogenous Src-PTK expres-
sion. Our results suggest that Lck’s distinctive ability to
promote DP development with high efficiency reflects
an inherent property of the Lck noncatalytic domains,
whereas SP development is most efficiently mediated by
enzymes bearing the Lck catalytic region. In addition, these
studies demonstrate that the relative accumulation of thy-
mocytes in CD4 or CD8 lineages is directly influenced by
the structure and dose of the PTK used to mediate signals
at DP to SP transition.
 
Materials and Methods
 
Construction of Chimeric Constructs. 
 
Plasmids NT-18 (35) and
MM23 (18) contain wild-type murine 
 
lck
 
 and 
 
fyn
 
T cDNAs, re-
spectively. Plasmids containing cDNAs encoding LckF505 (36)
or FynTF528 (25, 37) were used to produce chimeras bearing
phenylalanine substitutions at COOH-terminal regulatory ty-
rosine residues found in each respective kinase. To facilitate con-
struction of the chimeras, an NcoI restriction site was introduced
at the junction of the hinge and kinase domains in the murine
 
fyn
 
T cDNA by site-directed mutagenesis. An NcoI site is present
at the corresponding position of the 
 
lck
 
 cDNA. The NcoI-StuI
fragment from 
 
fyn
 
T was exchanged with the analogous fragment
in the 
 
lck
 
 cDNA by standard recombinant DNA technology. The
integrity of the resulting chimeric constructs was confirmed by
restriction mapping and sequencing.
 
Transfection and Transformation Assays. 
 
Chimeric PTKs were
cloned into the CMV-MNC expression vector using standard
techniques (38). DNA transfection of NIH-3T3 cells was per-
formed using a modified calcium phosphate precipitation tech-
nique (39), and transfected cells were selected in the presence of
500 
 
m
 
g/ml G418. To monitor focus formation, 10
 
3
 
 or 10
 
4
 
 NIH-
3T3 fibroblasts expressing each of the constructs were admixed
with 10
 
5
 
 NIH-3T3 cells transfected with the CMV-MNC base
vector, and were plated into 6-well plates in media containing
250 
 
m
 
g/ml G418. G418r foci were counted 10 d later. For
growth in soft agar, 2 
 
3
 
 10
 
4
 
 transfected cells were suspended in
growth medium containing 0.33% agar (Difco), and were over-
layed onto 0.55% agar gel as described previously (40). Colonies
were counted after 10 and 21 d.
 
Transgenic Mouse Production.
 
Lck
 
2
 
/
 
2
 
 and FynT
 
2
 
/
 
2
 
 mice have
been described previously (3, 20), as has the p1017 vector (18, 
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41). Chimeric PTK constructs were inserted into the BamHI site
of p1017. The transgene was released from the vector by NotI
digestion, purified, and injected into either C57BL/6J 
 
3
 
 DBA/2
F2 zygotes (construct Lck-fyn) or FVB zygotes (constructs Lck-
fyn
 
F
 
 and Fyn-lck
 
F
 
). Transgene-positive animals were identified
by PCR analysis (42), and lines were established by successive
backcrossing of transgene-positive animals to C57BL/6. Geno-
typing of animals for the presence of wild-type or disrupted Lck,
FynT, and Rag-1 alleles was similarly determined by PCR analy-
sis. All procedures were performed using protocols and standards
approved by the Institutional Animal Care and Use Committee
of the University of Maryland Institutional Review Board.
 
Northern Blot Analysis. 
 
Total RNA was isolated from mouse
thymocytes using TRIzol™ Reagent (Life Technologies). 15 
 
m
 
g
of RNA was resolved on 1% agarose formaldehyde gels, trans-
ferred to nylon membranes, hybridized, and washed according to
standard procedures. Regions of cDNA corresponding to NH
 
2
 
-
terminal or COOH-terminal coding sequences of 
 
lck
 
 or 
 
fyn
 
T
were labeled to high specific activity by random priming (43),
and were used as probes. Quantification was performed using a
PhosphorImager
 
®
 
 (Molecular Probes). Similar analyses failed to
reveal significant transgene expression in peripheral organs of the
mice.
 
Flow Cytometry. 
 
Single cell suspensions were obtained from
lymphoid organs as described (22). Thymocytes were stained for
surface expression of CD4, CD8, and CD3 molecules as de-
scribed previously (16), using PE-conjugated anti-CD4 (CT-
CD4), FITC-conjugated anti-CD8 (CT-CD8
 
a
 
), and biotiny-
lated anti-CD3
 
e
 
 (500.A2; all from Caltag Laboratories). Binding
of biotinylated antibodies was detected using streptavidin-Tri-
Color conjugate (Caltag Laboratories). Each analysis was per-
formed on 2 
 
3
 
 10
 
4 
 
events acquired in list mode using a FAC-
Sort™ flow cytometer, and was analyzed using CELLQuest™
software (Becton Dickinson).
 
Immunoblot Analysis. 
 
Thymocytes were lysed in NP-40 lysis
buffer (50 mM Tris, pH 7.4, 1% NP-40, 150 mM NaCl, 1 mM
EGTA, 1 mM PMSF, 1 
 
m
 
g/ml aprotinin and leupeptin, 1 mM
NaF, and 1 mM Na
 
3
 
VO
 
4
 
). Samples were gently rocked on ice for
30 min, and were centrifuged at 12,000 rpm for 10 min at 4
 
8
 
C.
Total protein concentrations in the supernatants were determined
using a modified Lowry assay (Bio-Rad). Cell lysates were sepa-
rated by SDS-PAGE, and were transferred to nitrocellulose
membranes. An mAb specific for the NH
 
2
 
-terminal region of
p56
 
lck 
 
(Santa Cruz Biotechnology), rabbit antisera specific for the
COOH-terminal region of human p56
 
lck
 
 (Upstate Biotechnol-
ogy) or mouse p56
 
lck
 
 (35), and specific Ab for Fyn (Santa Cruz
Biotechnology) were used to document expression of the chi-
meric kinases. The blots were developed using enhanced chemi-
luminescence (Amersham Pharmacia Biotech). Densitometric
analyses of immunoblots verified that when expressed at similar
mRNA concentrations, wild-type Lck, Lck-fyn, and Fyn-lck
 
F
 
proteins accumulate to comparable levels in Lck
 
1
 
/
 
2
 
, Lck
 
2
 
/
 
2
 
[A10247], and Lck
 
2
 
/
 
2
 
[116] strains, respectively. Dose-matched
levels of Lck-fyn
 
F
 
 transcripts yielded a somewhat lower steady-
state kinase accumulation (0.17 Lck-Fyn
 
F
 
:Lck
 
1
 
/
 
2
 
) when mea-
sured in Lck
 
2
 
/
 
2
 
[490] mice.
 
Results
 
Lck/Fyn Chimeras Have Differing Transforming Efficiencies
in NIH-3T3 Fibroblasts.
 
To monitor the contribution of
Src-PTK domains to Lck thymopoietic function, chimeric
kinases were produced by exchanging catalytic domains
between Lck and the related Src-PTK FynT (Fig. 1 A).
The Lck-fyn construct carries a replacement of amino acids
234–510 of Lck with corresponding residues 257–534 of
FynT, generating a chimera consisting of the Lck NH
 
2
 
-ter-
Figure 1. (A) Schematic representation of
parental and Lck/Fyn chimeric structures.
wt, wild-type; U, unique. (B) Transforming
efficiency of Src-PTKs in NIH-3T3 fibro-
blasts as measured in focus formation and
soft agar growth assays. (C) Expression of
transgene-encoded mRNAs in thymocytes
from littermates representing indicated geno-
types. Northern blot analysis using probes
specific for the NH2-terminal regions of Lck
or the COOH-terminal regions of FynT (left), or probes specific for the COOH-terminal regions of Lck or the NH2-terminal region of FynT (right).
LFY, Lck-fyn chimera; FLF, Fyn-lckF chimera; Tg, transgene. (D) Immunoblot (IB) analysis of chimera expression using antibodies specific for NH2-ter-
minal (NT) or COOH-terminal (CT) regions of p56lck. 
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minal regions fused to the Fyn catalytic domain. The recip-
rocal construct Fyn-lck substitutes residues 255–534 of
FynT with amino acids 232–510 of Lck, encoding a chi-
mera in which the NH
 
2
 
-terminal regions of Fyn have been
fused to the Lck catalytic domain. In addition, as the effi-
ciency of enzyme autorepression may be altered in chime-
ras containing SH2 and COOH-terminal regulatory do-
mains recovered from heterologous sources (44), we also
produced genetically derepressed versions of these recom-
binant PTKs, in which the regulatory COOH-terminal ty-
rosine residue was substituted with phenylalanine (Lck-fynF
and Fyn-lckF).
Fidelity of the chimeric constructs was examined after
cloning of the recombinant Src-PTKs into expression vec-
tors and transfection of the constructs into the NIH-3T3 fi-
broblast cell line. Stable fibroblast clones expressing each
kinase were obtained after drug selection, and immuno-
blotting with antibodies specific for NH2-terminal or
COOH-terminal regions of p56lck and p59fynT confirmed
that all chimeras were expressed in correct immunoreactive
forms in these cells (data not shown). Src-PTK function
was evaluated in this context by measuring the transform-
ing efficiency of individual PTK constructs in focus forma-
tion and soft agar growth assays. Consistent with previous
reports (36, 45), expression of wild-type forms of Lck and
FynT did not promote transformation of NIH-3T3 cells,
whereas parental enzymes bearing Tyr to Phe substitutions
at COOH-terminal regulatory tyrosine residues behaved as
dominant oncogenes in the fibroblasts (Lck-lckF and Fyn-
fynF; Fig. 1 B). Both Fyn-lck and Fyn-lckF were as potent
as the mutant parental enzymes in transforming NIH-3T3
cells, suggesting that both chimeras behave as activated ki-
nases in fibroblasts. In contrast, neither Lck-fyn nor Lck-
fynF was transforming as measured by these criteria. The
inability of Lck-fyn PTKs to transform NIH-3T3 cells does
not reflect a grossly aberrant conformation or loss of kinase
activity in these chimeras, as both Lck-fyn and Lck-fynF
operate efficiently in the lymphocyte background (see be-
low). Rather, this phenotype in fibroblasts likely reflects a
negative impact of Lck NH2-terminal regions on Fyn cata-
lytic function in these cells, a phenomenon similarly noted
on analysis of chimeras bearing Lck regulatory domains
coupled to the Src catalytic region (32).
Generation of Lck Mutant Mice Expressing Chimeric PTKs.
The ability of the chimeric PTKs to influence thy-
mocyte  development was examined first in transgenic mice
expressing these enzymes under the control of the lck prox-
imal promoter. Lck gene expression is regulated by two
promoter elements, proximal and distal (46–48), and se-
quences including the proximal promoter element have
been used to direct expression of a variety of heterologous
genes in thymocytes of transgenic mice (vector p1017 [18,
41]). The chimeric PTK constructs were inserted into the
p1017 vector and then injected into zygotes, and transgenic
lines expressing Lck-fyn, Lck-fynF, and Fyn-lckF were ob-
tained. Transgenic mice expressing the chimeras did not
exhibit major changes in thymus size and cellularity, and
transgene expression did not significantly alter thymocyte
subset representation with respect to CD3, CD4, and CD8
expression (Table I; data not shown).
Chimera function was examined subsequently by doc-
umenting the ability of individual PTKs to reconstitute
thymopoiesis in Lck2/2 mice (3). Levels of chimera
mRNA expression were defined relative to endogenous
Lck through simultaneous measurement of endogenous
and transgene-derived PTK expression in thymocytes of
transgene-positive Lck1/2 progeny (Fig. 1 C; summarized
in Table I). Consistent with previous reports (3), no Lck
protein, either full-length or truncated, was detected in
Table I. Reconstitution of Lck2/2 Thymopoiesis with Src-PTK 
Transgenes
Transgenic line
(Chimera)
Transgene
mRNA* Genotype‡ n§
No. of
thymocytesi
mean % 6 SD
A10247 0.18 Lck-fyn 11 89 6 29
(Lck-fyn) lck2/2 Lck-fyn 5 1.9 6 4
A10247 (23) 0.36 Lck-fyn 1 95
(Lck-fyn) lck2/2 Lck-fyn 2 11.5 6 5
A10244 0.87 Lck-fyn 8 98 6 38
(Lck-fyn) lck2/2 Lck-fyn 3 67 6 24
A10262 4.45 Lck-fyn 5 67 6 23
(Lck-fyn) lck2/2 Lck-fyn 5 56 6 25
490 1.02 Lck-fynF 9 131 6 33
(Lck-fynF) lck2/2 Lck-fynF 3 98 6 25
116 Fyn-lckF 7 90 6 32
(Fyn-lckF) 0.96 lck2/2 Fyn-lckF 4 2.1 6 0.4
668 Fyn-lckF 5 120 6 13
(Fyn-lckF) 2.20 lck2/2 Fyn-lckF 3 4.3 6 1.0
687 3.50 Fyn-lckF 3 82 6 24
(Fyn-lckF) lck2/2 Fyn-lckF 3 4.7 6 1.8
685 5.32 Fyn-lckF 7 132 6 33
(Fyn-lckF) lck2/2 Fyn-lckF 8 12.9 6 1.9
*Transgene mRNA expression relative to endogenous Lck1/2 mRNA
levels as determined by PhosphorImager® analysis of Northern blots.
‡Determined by PCR analysis of tail DNAs.
§Numbers of animals of indicated genotypes analyzed to date.
iTotal thymocyte numbers were determined in animals of indicated
genotypes at 3–4 wk of age. Values represent the number of thy-
mocytes recovered from animals of indicated genotypes expressed as a
percentage of the normal control littermate mean value obtained within
each cross (lck1/1;1/2). Value of lck2/2 littermates (combined prog-
eny from all crosses) 2.9 6 0.96 (n 5 17).707 Lin et al.
Lck2/2 mice when immunoblots were probed using anti-
sera specific for either the NH2-terminal or COOH-termi-
nal region of Lck (Fig. 1 D). However, a large transcript
could be detected by probes specific for either the NH2-
terminal or COOH-terminal region of the lck mRNA in
these mice (Fig. 1 C), presumably reflecting lck transcripts
containing the neoR cassette in exon 12. Expression of the
chimeric PTK transgenes was documented by the appear-
ance of transcripts slightly larger than the wild-type lck
mRNA (Fig. 1 C), and by detection of chimeric proteins
reactive with antiserum specific for either NH2-terminal
(Lck-fyn and Lck-fynF) or COOH-terminal regions of Lck
(Fyn-lckF) in Lck2/2 mice (Fig. 1 D; data not shown).
Lck-fyn Restores DP Development in Lck Mutant Mice. As
reported previously, thymocyte numbers are drastically re-
duced in Lck mutant mice, with the remaining cells distrib-
uted between DN (70%) and DP (30–80%) compartments
(Fig. 2, and Table I; references 3, 8). One allele of wild-
type Lck is sufficient to restore normal thymocyte numbers
and subset representation in these mice (Lck1/2; Fig. 2, and
reference 3), suggesting that one allele represents a maximal
Lck dose necessary to efficiently rescue Lck2/2 thymopoie-
sis. Accordingly, we have assayed chimera function at
transgene doses that approximate PTK expression from a
single Lck allele in an effort to enhance the sensitivity of
our in vivo analysis. Significantly, many aspects of Lck2/2
thymopoiesis could be restored by expression of the Lck-
fyn PTK at this physiological dose (Lck-fyn[0.87]; Fig. 2). An
increase in DP cell numbers and a proportional shift of thy-
mocytes between DN and DP compartments occurred
when Lck-fyn[0.87] was expressed in the Lck2/2 strain (Fig.
2, and Table I). In addition, transgene-dependent changes
in Lck2/2 thymocyte size were observed coincident with
the appearance of DP and SP subsets in Lck-fyn1 Lck2/2
mice (Fig. 2). Thus, the Lck-fyn PTK efficiently relays pre-
TCR signals that are necessary to mediate two key facets of
the DN to DP transition: cellular expansion, and acquisi-
tion of CD4 and CD8 expression.
Surface CD3 expression is increased in Lck2/2 thy-
mocytes (Fig. 2; reference 3), a phenomenon that reflects
the impact of Lck signals on CD3 surface density (8, 49).
Like wild-type Lck, the Lck-fyn PTK modulates surface
CD3 expression in Lck2/2 thymocytes (Fig. 2). Thus, al-
though endogenous Fyn cannot appropriately regulate
CD3 density in the absence of Lck, CD3 expression is nor-
malized when the Fyn catalytic region is expressed in the
context of Lck NH2-terminal domains (the Lck-fyn chi-
mera). This finding indicates that Fyn’s inability to modu-
late CD3 density cannot be ascribed to a major deficiency
of the Fyn catalytic region.
Figure 2. Reconstitution of Lck2/2 thymopoiesis using Lck-fyn and Fyn-lck chimeras. Thymocytes were recovered from animals of indicated geno-
types, and were counted and analyzed by flow cytometry. Shown are representative flow cytometric profiles of thymocyte forward scatter (FSC, top),
CD4 and CD8 expression (middle), and CD3 density (bottom). Numbers of thymocytes recovered in each analysis are indicated.708 Lck Domains Influencing Thymopoietic Efficiency
Lck-fyn and Lck-fynF Fail to Fully Restore SP Development
in Lck Mutant Mice. Although DP production and normal
TCR/CD3 expression were restored by Lck-fyn[0.87],
fewer SP thymocytes accumulate in this strain (17% in
Lck1/2 versus 6% in Lck-fyn[0.87]; Fig. 2). The suboptimal
rescue of SP cells observed at this chimera dose cannot be
attributed either to the suballelic level of PTK expression
achieved in the cross, or to modulation of transgene pro-
moter activity at positive selection (50), as no improvement
in SP production was observed in Lck2/2 animals express-
ing Lck-fyn at four to five times higher levels (strain
A10262 Lck-fyn[4.45]; Table I, and data not shown). Thus,
the inability of Lck-fyn to mediate full reconstitution of SP
thymocytes appears to reflect a deficiency in the Lck-fyn
structure that preferentially impacts SP production. To ex-
amine Lck-fyn PTK efficiency in greater detail, a constitu-
tively active form of the Lck-fyn kinase was produced
(Lck-fynF), and its function was monitored in the Lck2/2
background.
Expression of this activated mutant form of Lck-fyn
(construct Lck-fynF) also restored wild-type DP numbers in
Lck2/2 mice (Fig. 2). Although DN to DP transition was
effectively mediated by Lck-fynF, this PTK structure once
again failed to fully restore SP development. Taken to-
gether, these findings suggest that substitution of the Lck
catalytic and COOH-terminal regulatory regions with
FynT sequences has minimal impact on the efficiency of
pre-TCR signaling as measured by development and ex-
pansion of DP thymocytes. The fact that SP production is
not similarly restored using this PTK further suggests that
DN to DP and DP to SP transitions have differential re-
quirements for Lck structures or catalytic activities.
Fyn-lckF Mediates DN to DP Transition, but Fails to Recon-
stitute DP Thymocyte Numbers in Lck Mutant Mice. As sub-
stitution of the Lck catalytic region with FynT domains ap-
peared to have a negligible impact on pre-TCR signaling,
we next examined the contribution of Lck noncatalytic do-
mains to this process. Accordingly, a chimera consisting of
the Fyn NH2-terminal regions fused to the Lck catalytic
domain was produced (Fyn-lckF), and the ability of this
PTK to restore thymopoiesis in the Lck mutant back-
ground was monitored. Despite its potent transforming ef-
fects in NIH-3T3 cells (Fig. 1 B), Fyn-lckF failed to restore
thymopoiesis in Lck2/2 mice when expressed at levels ap-
proximating a single allele of Lck (Fig. 2, Fyn-lckF
[0.96]).
Thus, in contrast to the effects of Lck-fyn and Lck-fynF at
this gene dose, DP numbers were not increased in Lck2/2
mice expressing Fyn-lckF
[0.96]. These differential activities
of the chimeras cannot be ascribed to major differences in
protein stability, as in agreement with their mRNA levels,
both Lck-fyn[0.87] and Fyn-lckF
[0.96] yield a degree of PTK
protein accumulation that is comparable to one allele of
Lck (see Materials and Methods; data not shown). None-
theless, the DP compartment was not restored in Fyn-
lckF
[0.96]:Lck2/2 mice. However, a slight but appreciable
enhancement in DN to DP transition and a transgene-
dependent modulation of thymocyte CD3 density were ob-
served in this reconstituted strain (Fig. 2). These findings
suggested the possibility that Fyn-lckF may be able to sub-
serve some Lck functions at DN to DP transition, albeit
with low efficiency.
To examine Fyn-lckF thymopoietic efficiency in greater
detail, the dose of Fyn-lckF introduced into the Lck2/2
background was raised incrementally, and thymocyte de-
velopment was monitored in these reconstituted strains
(Fig. 3, and Table I). Fyn-lckF failed to reconstitute thymus
cellularity at any dose tested, including expression levels
that exceeded by five times the amount of wild-type Lck,
Lck-fyn, or Lck-fynF required to restore DP numbers
(Fyn-lckF
[5.32] versus Lck-fyn[0.87] and Lck-fynF
[1.02]; Table
I). However, a transgene dose–dependent restoration of
CD3 density and DN to DP differentiation occurred in
Fyn-LckF:Lck2/2 strains lacking full reconstitution of the
DP compartment. For example, CD3 density was modu-
lated in Lck2/2 CD41CD81 thymocytes in the presence of
Fyn-lckF[0.96], and became normalized at Fyn-lckF
[2.2],
whereas reconstitution of wild-type proportions of DN and
DP cells appeared to require higher levels of transgene ex-
pression (Fig. 3, Fyn-lckF
[3.5]). These findings demonstrate
that the structure and dose of the Src-PTK expressed dif-
ferentially impacts CD3 density, DN to DP differentiation,
and proliferative expansion of developing thymocytes.
Fyn-lckF Mediates DP to SP Transition in Lck Mutant
Mice. A transgene-dependent recovery of SP production
was observed when Fyn-lckF expression was raised from
[0.96] to [3.50]; representation of SP thymocytes in Lck2/2
increases from ,1% at Fyn-lckF
[0.96]  to 5–7% at Fyn-
lckF
[2.2], and reaches wild-type proportions at Fyn-lckF
[3.5]
(Fig. 3; data not shown). Our preliminary analysis of ani-
mals expressing Fyn-lckF at [4.4] (Fyn-lckF
[2.2] homozy-
gotes) is also consistent with this apparent dose-dependent
relationship between Fyn-lckF expression and SP genera-
tion, as Fyn-lckF
[4.4] and Fyn-lckF
[3.5] yield similar propor-
tions of SPs in the Lck2/2 background (data not shown).
The fact that a higher level of Fyn-lckF expression was re-
quired to effect DP to SP transition than was necessary to
influence DN to DP transition suggests that, although both
differentiation programs possess overlapping characteris-
tics, DP to SP transition may be a more stringent process,
requiring higher levels of kinase expression or activity. In-
terestingly, accumulation of the CD8 SP subset is enhanced
relative to the CD4 subset when Fyn-lckF is substituted for
Lck during DP to SP transition (Fig. 3). CD4/CD8 ratios
of ,1.0 are routinely observed in CD31 thymocytes pro-
duced via Fyn-lckF
[2.2], Fyn-lckF
[3.5], and Fyn-lckF
[5.32] activ-
ity. Thus, the natural bias in thymopoiesis toward genera-
tion of CD4 SPs appears to be a phenotype superimposed
on thymic selection by PTKs bearing Lck NH2-terminal
domains. When SP selection operates in the absence of
wild-type Lck, as for example in the case of Lck2/2:Fyn-
lckF
[3.5], this bias is minimized to yield a CD4/CD8 ratio of
0.79 6 0.28 (mean 6 SD, n 5 4; Fig. 3; data not shown).
CD3 density is upregulated during repertoire selection as
cells transition from DP to SP stages of development (51).709 Lin et al.
However, SP subsets selected by Fyn-lckF in the absence of
Lck failed to express wild-type levels of surface CD3 (Fig.
3). This finding indicates that signals required to upregulate
CD3 density at DP to SP transition may be distinguished
from signals necessary to mediate coreceptor modulation
by their differential dependence on PTK activity. In sup-
port of this view, a recent study revealed a correlation be-
tween mitogen-activated protein kinase kinase (MEK)
activity and the extent of CD3 upregulation in SP thy-
mocytes (52), suggesting that inefficient transduction of
signals to MEK may underlie the inability of Fyn-lckF to
fully upregulate CD3 density at DP to SP transition.
Src-PTK Collaboration in Lck2/2 Thymocyte Differentiation.
As the majority of kinase structure in Fyn-lckF is con-
tributed by Fyn sequences, we considered the possibility
that Fyn-lckF function in Lck2/2 thymocytes could be in-
fluenced by the presence of endogenous Fyn. This influence
could take the form of enhancing chimera function through
collaborative effects, or of inhibiting chimera function
through dominant negative interference. To test this possi-
bility, dose-dependent effects of Fyn-lckF transgene expres-
sion were monitored in Lck2/2Fyn2/2 mice, and results
were compared with analyses performed in mice expressing
one or both wild-type Fyn alleles (Fig. 4). As described pre-
viously, DPs were virtually absent in Lck2/2Fyn2/2 mice
(Fig. 4 A; references 24, 25). Notably, we observed a repro-
ducible, dose-dependent effect of Fyn expression in the
Lck2/2 background (from 39% DPs in Lck2/2Fyn1/2 to
65% DPs in Lck2/2Fyn1/1). This dose-dependent effect of
Fyn alleles in Lck2/2 was not apparent in prior analyses of
Lck2/2Fyn2/2 recombinant strains. We believe this dis-
crepancy may reflect the influence of background gene ef-
Figure 3. Dose-dependent effects of Fyn-lckF chimera expression in Lck2/2 mice. Thymocytes were recovered from animals of indicated genotypes,
and were analyzed by flow cytometry. Shown are representative flow cytometric profiles depicting thymocyte forward scatter (FSC), CD4 and CD8
expression, and CD3 density as determined using three-color immunofluorescence. Numbers of CD31CD41 or CD81 thymocytes observed in equiv-
alent flow cytometric analyses of Lck2/2 animals expressing Fyn-lckF at [2.2], [3.5], and [5.32] are shown, with CD3 density expressed as mean channel
fluorescence (MCF). CD41 and CD81 thymocytes did not accumulate at levels that were sufficient to permit a similar analysis of CD3 density in ani-
mals expressing Fyn-lckF[0.96].710 Lck Domains Influencing Thymopoietic Efficiency
fects contributed by the founder knockout strains, as the
severity and reproducibility of both the Lck2/2Fyn1/1
and Lck2/2Fyn1/2 developmental arrests increase as the
Lck2/2 and FynT2/2 parental strains are continually back-
crossed to C57BL/6. Accordingly, we have limited our
analyses to reconstitutions in which the transgenes and dis-
rupted alleles are contributed by parental strains that have
been backcrossed to C57BL/6 for at least four or five gener-
ations.
The ability of Fyn-lckF
[0.96] to promote DN to DP transi-
tion is easily appreciated in the Lck2/2Fyn2/2 background
(Fig. 4 A). Moreover, endogenous Fyn enhanced Fyn-lckF’s
ability to promote DN to DP transition in what appeared to
be an additive fashion. Although both Fyn-lckF
[0.96] and one
allele of wild-type Fyn enhanced transition into the DP
compartment in Lck2/2, generating 42.7 and 28.9% DPs,
respectively (Fig. 4 A), their combination yielded 68.1%
DPs (Lck2/2Fyn1/2 Fyn-lckF
[0.96]). This increment in Fyn-
lckF DN to DP differentiative function was not appreciably
changed by introduction of the second Fyn allele (Lck2/2
Fyn1/1), and further evidence of enhanced Fyn-lckF func-
tion, such as generation of SPs, was not observed.
SPs emerged in the Lck2/2Fyn2/2 background only as
the level of Fyn-lckF was increased, with wild-type propor-
tions once again observed at Fyn-lckF
[3.5]. The additive ef-
fects of endogenous Fyn and Fyn-lckF
[3.5] appear to influ-
Figure 4. Endogenous Fyn enhances Fyn-lckF func-
tion in Lck2/2 mice. (A, top) FynT enhances Fyn-lckF–
mediated thymocyte differentiation. Thymocytes were
recovered from animals of indicated genotypes and were
analyzed by flow cytometry. Shown are representative
flow cytometric profiles depicting CD4 and CD8 ex-
pression determined in three-color immunofluorescence
analyses as described in the legends to Figs. 2 and 3.
Numbers of thymocytes recovered from animals in each
experimental group are shown beneath the correspond-
ing dual parameter histograms (mean 3 1026 6 SD). (A,
bottom) A cumulative analysis of DN and DP propor-
tions in mouse strains as determined by flow cytometry
(mean percentage 6 SD; n = number of animals of indi-
cated genotypes analyzed). Statistical analyses by two-
sample t tests verify that expression of Fyn-lckF is associ-
ated with a significant increase in DP thymocytes in both
Lck2/2Fyn2/2 ([0.96], P 5 0.005; [3.5], P 5 ,0.001)
and Lck2/2Fyn1/2 mice ([0.96], P 5 ,0.001), and that
there is a statistically significant impact of Fyn alleles on
DP generation in the presence of Fyn-lckF activity (P 5
0.009). (B) FynT modulates Fyn-lckF–mediated prolifer-
ative expansion. Thymocyte cellularity (C) in reconsti-
tuted strains plotted as a function of chimera RNA ex-
pression levels. Symbols are mean percentages (adapted
from Table I).711 Lin et al.
ence the extent of CD8 SP bias associated with Fyn-lckF
activity (Fig. 3). Although CD4 and CD8 SPs were pro-
duced in equivalent proportions in Fyn-lckF
[3.5] mice lack-
ing both Lck and Fyn (Fyn-lckF
[3.5]:Lck2/2Fyn2/2), a rela-
tive enrichment in CD8 SPs was observed in Fyn-lckF
[3.5]:
Lck2/2Fyn1/1 mice (Fig. 4 A). As observed previously in
the Lck2/2Fyn1/1 background, signals generated by Fyn-
lckF in Lck2/2Fyn2/2 mice were sufficient to mediate
coreceptor modulation, but failed to fully upregulate CD3
in either SP subset (Fig. 4; data not shown). Because CD69
density is upregulated in these cells (data not shown), we
speculate that the phenotype of Fyn-lckF[3.5]:Lck2/2Fyn2/2
SP thymocytes reflects the outcome of a DP to SP transi-
tion event in which signals were initiated via the Ras path-
way (CD69hi [53]), but failed to sustain full activation of
MEK (CD3lo [52]).
Although Fyn-lckF could mediate both DN to DP and
DP to SP transitions in Lck2/2Fyn2/2 mice, this kinase
once again failed to reconstitute proliferative expansion in
this background (Fig. 4, A and B). Moreover, parallel anal-
yses of Fyn-lckF–mediated thymocyte expansion in the
Lck2/2 and Lck2/2Fyn2/2 backgrounds suggest that the
modest proliferative signals associated with Fyn-lckF
[0.96]
and Fyn-lckF
[3.5] were reduced in the presence of endoge-
nous Fyn (by two to three times; Fig. 4, A and B). We
conclude that endogenous Fyn influences Fyn-lckF func-
tion in two ways: (a) by facilitating Fyn-lckF–mediated DN
to DP transition signals, and (b) by modulating Fyn-lckF–
mediated proliferative expansion signals.
Pre-TCR Regulation of Chimeric PTK Function. Trans-
genic expression of activated mutant Lck (LckF) promotes
DP development in the absence of pre-TCR formation,
such as in mice lacking TCR-b or pre–TCR-a expression
(strain LGF 2954 [8, 54]). These findings have supported
the general view that Lck activation is a key event induced
by the pre-TCR at DN to DP transition. As high levels of
PTK activity can bypass the requirement for pre-TCR for-
mation at DN to DP transition, we asked whether the pre-
TCR was required to mediate DP development in the
presence of the chimeric PTKs. The contribution of the
pre-TCR to Lck-fynF– or Fyn-lckF–dependent DP pro-
duction was measured by comparing the ability of the chi-
meras to promote DN to DP transition in the presence or
absence of pre-TCR assembly in PTK2/2  or Rag2/2
strains, respectively (Fig. 5).
Importantly, although Lck-fynF efficiently restored DP
production in Lck2/2 mice (Fig. 2), this kinase failed to re-
constitute the DP compartment in the Rag2/2 background
at either dose tested (Lck-fynF
[1.02] and Lck-fynF
[2.04]; Fig.
5). We conclude that Lck-fynF promotes DN to DP transi-
tion in Lck2/2 mice through processes that require pre-
TCR–dependent regulation of Lck-fynF activity. In con-
trast, a dose-dependent increase in DP production was
apparent in Rag2/2 mice expressing the Fyn-lckF trans-
gene. As shown above, Fyn-lckF
[0.96] dramatically increased
DN to DP transition in Lck2/2Fyn2/2 mice (from 0.89 to
50.32% DP; Fig. 4 A). Rag2/2 mice expressing Fyn-lckF at
this concentration exhibited a modest, but nonetheless ap-
preciable transgene-dependent increase in DP production
(from 0.29 to 13.47% DP in transgene-negative and trans-
gene-positive, respectively), indicating that Fyn-lckF can
mediate DN to DP transition in the absence of pre-TCR
assembly, but with low efficiency. As pre-TCR expression
facilitates Fyn-lckF
[0.96] function at DN to DP transition, we
conclude that the Fyn-lckF chimera retains sequences that
are necessary to functionally couple the pre-TCR to a sub-
set of intracellular transduction pathways.
Importantly, phenotypes associated with overexpression
of LckF emerge when Fyn-lckF expression is raised five
times to the levels achieved in Fyn-lckF
[5.32]. These LckF-
associated phenotypes include a relative accumulation of
DN thymocytes (Fig. 3) and production of DP thymocytes
in Rag2/2 mice (to 52% in Rag2/2 Fyn-lckF
[5.32]; Fig. 5;
references 8, 22). Similar phenotypes are observed in ani-
mals expressing Fyn-lckF at levels .5.32, such as mice ho-
mozygous for the Fyn-lckF
[3.5] transgene (Fyn-lckF
[7.0]; data
not shown). Thus, titration of Fyn-lckF into Lck2/2 at
doses that exceed a range of Lck expression of between one
and four allele equivalents (.[0.96], [2.20], [3.5], and [4.4])
Figure 5. DP production in the absence of pre-TCR assembly. Thy-
mocytes from Rag1/2, Rag2/2, and Rag2/2 mice expressing chimeras at
indicated concentrations were recovered, counted, and analyzed by flow
cytometry. Shown are representative dual parameter flow cytometric pro-
files depicting CD4 and CD8 expression in each strain. Cellularity (C) is
expressed as a percentage of thymocyte numbers recovered from non-
transgenic Rag1/2 littermates. In each case, the data are representative of
at least three independently derived transgene-positive Rag2/2 progeny.712 Lck Domains Influencing Thymopoietic Efficiency
yields a phenotype that is reminiscent of LckF overexpres-
sion (22). Nonetheless, unlike LckF, the Fyn-lckF enzyme
structure fails to signal efficient cellular expansion in either
Lck2/2 or Rag2/2 mice at these high doses (Fig. 4 B and
Fig. 5). Taken together, these findings suggest that al-
though Fyn-lckF lacks structures required to relay signals to
the cell cycle, the enzyme may retain sequences that are
necessary to link the PTK to signaling phenomena previ-
ously associated with Lck hyperactivity, such as pathways
regulating rearrangement at the TCR-b locus (7, 22).
Discussion
Several lines of evidence indicate that expression of the
TCR b chain is necessary for efficient progression from
CD42CD82 DN to CD41CD81 DP stages of a/b thy-
mocyte development. These b chain–associated matura-
tional changes are dependent on formation of a pre-TCR
complex consisting of TCR-b, pre-Ta, and CD3 compo-
nents, and on expression of Lck (for a review, see reference
9). In this report, we define the relative contributions of
catalytic versus noncatalytic domains to Lck functions in
thymopoiesis by monitoring the activity of recombinant
chimeric PTKs in PTK-deficient mouse strains. Our obser-
vations support the view that among the Src-PTKs, Lck is
specialized in its ability to promote DN to DP develop-
ment with high efficiency, and that this functional distinc-
tion is encoded within the Lck noncatalytic regions. In ad-
dition, the ability of the pre-TCR to regulate proliferative
expansion is most profoundly dependent on the participa-
tion of a Src-PTK bearing Lck NH2-terminal domains.
The ability of Src-PTKs to transform fibroblasts does not
correlate with their functional efficiency in the lymphocyte
background. Although only activated forms of Lck and
FynT are capable of transforming NIH-3T3 cells (COOH-
terminal Y®F), both wild-type and activated forms of Lck
induce thymic tumorigenesis when overexpressed in trans-
genic thymocytes (55). Neither wild-type nor constitu-
tively active FynT readily promotes lymphocyte transfor-
mation (18, 25). Accordingly, the transforming ability of
the chimeric kinases in fibroblasts is inversely related to
their ability to promote maturation of Lck-deficient thy-
mocytes. As a corollary to the diminished effectiveness of
Lck in thymocytes that results when Fyn noncatalytic re-
gions are affixed to the Lck catalytic domain, the potent
transforming ability of FynT is dramatically decreased in fi-
broblasts when noncatalytic regions of Lck are substituted
into the FynT structure. These apparent inhibitory effects
of the Lck regulatory domains on FynT transforming activ-
ity indicate that specialized functions are imparted to Fyn
by its noncatalytic regions that cannot be substituted by
Lck domains within the fibroblast cellular context. This
view is consistent with the fact that FynB is normally ex-
pressed in fibroblasts, whereas Lck is not. Similar inhibitory
effects of the Lck SH3 domain have been observed in fi-
broblasts expressing Lck-Src chimeras (32).
The presence of small numbers of DP thymocytes in Lck
mutant mice prompted speculation that kinases such as Itk/
Tsk (56, 57) or Zap-70 (58) may compensate for loss of
Lck during thymopoiesis (8). Consistent with previous re-
ports (24, 25), our data identifies the Src-PTK FynT as the
compensatory element required for generation of Lck2/2
DP cells. The fact that endogenous FynT cannot fully
compensate for Lck loss at DN to DP transition could re-
flect an inadequate level of FynT expression, a functional
deficiency in FynT, or a combination of these characteris-
tics. Indeed, transgenic expression of activated mutant
FynT in Lck2/2 increases DP production (25), suggesting
that apparent differences in Fyn and Lck potency might
simply reflect their differing expression levels in DN thy-
mocytes. However, striking differences in Fyn and Lck po-
tency are apparent when dose-dependent effects of the two
activated mutant PTKs are compared (22, 25, 55), suggest-
ing that intrinsic differences in these two enzyme structures
likely impact their differential thymopoietic activities.
Fyn exists as two isoforms that differ in their alternative
usage of Fyn exon 7a (FynB) or 7b (FynT). These isoforms
differ exclusively within a sequence of z50 amino acids
overlapping the end of the SH2 and beginning of the cata-
lytic domains (37, 59). The hematopoietic isoform FynT is
the only PTK in which the last glycine of the canonical
GXGXXG motif (glycine 280) found in the catalytic re-
gion is replaced by alanine (60). By creation and analysis of
FynT-FynB chimeras, it was determined that it is the dis-
tinctive FynT catalytic domain and not its divergent SH2
motif that confers improved FynT biological function dur-
ing antigen stimulation (59). Based on these findings, it was
suggested that the enhanced catalytic function of FynT may
be directed toward a limited subset of TCR-regulated sub-
strates.
Our data demonstrate that when expressed in the con-
text of the Lck regulatory domains, the distinctive FynT
catalytic region directs DN to DP transition with an effi-
ciency and fidelity that is indistinguishable from the Lck
catalytic region. These results indicate that differences in
Lck and Fyn thymopoietic potency that impact DN to DP
transition are not inherent properties of the individual cata-
lytic domains. Nonetheless, it is clear that the Fyn catalytic
region does not completely duplicate Lck catalytic domain
function, as enzymes containing this region fail to effi-
ciently promote development of SP thymocytes. The fact
that DP to SP transition cannot be effectively restored by
PTK structures that efficiently mediate DN to DP transi-
tion indicates that these two developmental processes have
distinctive PTK requirements. These differential require-
ments could be imposed by the need to transduce signals
downstream of unique receptor structures at each transition
(the pre-TCR versus the TCR-a/b), by the participation
of additional PTK-coupled receptors (such as CD4/CD8),
or by the need to interact with unique substrates, effectors,
or regulators of kinase activity at each developmental stage.
As their catalytic domains appear to operate interchange-
ably at DN to DP transition, it is apparent that functional
distinctions between Lck and FynT that impact this stage of713 Lin et al.
development reflect individual or cooperative characteris-
tics of the PTK noncatalytic regions. In support of this
view, transgene dose–response curves demonstrate that
PTKs containing FynT NH2-terminal domains are 5–20
times less efficient in reconstituting Lck2/2 thymopoiesis
than enzymes containing the Lck NH2-terminal domains.
This difference cannot be attributed to interference from
endogenous Fyn, and in fact endogenous Fyn assists in pro-
moting Fyn-lckF–dependent DN to DP transition. The
possibility that apparent differences in Lck and Fyn NH2-
terminal domain functions may reflect both quantitative
and qualitatitive distinctions is supported by the finding
that activated FynT can restore some aspects of Lck2/2
thymopoiesis, including pre-TCR–dependent differentia-
tion and proliferation (25). As the level of FynTF expres-
sion was not quantitated relative to endogenous Lck in the
experiments, and only a single dose of FynTF was used, it is
impossible to deduce whether FynTF is more or less potent
than Fyn-lckF in mediating pre-TCR signals. Nonetheless,
it is apparent that the thymopoietic efficiency of activated
mutant Fyn is substantially inferior compared with wild-
type and activated Lck (22) and Lck-fyn (this report).
Moreover, our data convincingly demonstrate that, when
operating in the context of the same catalytic domain, the
Fyn and Lck NH2-terminal regions exhibit striking func-
tional differences that impact the efficiency of pre-TCR
signaling.
Pre-TCR assembly appears to regulate the majority of
DP development associated with Fyn-lckF
[0.96] kinase activ-
ity. This finding suggests that triggering of PTK activation
by the pre-TCR may not be dramatically affected by sub-
stitution of the Lck NH2-terminal regions with FynT do-
mains. However, proliferative expansion does not occur
when the Fyn-lckF kinase is used by the pre-TCR, indicat-
ing that kinases containing the FynT NH2-terminal regions
fail to efficiently engage those downstream signaling path-
ways that are necessary to initiate this expansion event. Im-
portantly, although proliferative signals are dramatically
compromised when PTKs containing FynT NH2-terminal
domains provide pre-TCR signals, this enzyme structure is
relatively efficient in directing DN to DP transition. As sig-
nals generated by this PTK are both regulated by pre-TCR
assembly and sufficient to signal upregulation of CD4 and
CD8 expression, we conclude that this enzyme structure
can couple to the pre-TCR and relay signals to down-
stream signaling pathways. The fact that the PTK signals
transduced are sufficient to stimulate developmental transi-
tion but fail to signal proliferative expansion suggests that
these two outcomes of pre-TCR signaling require either
differing thresholds of kinase activity or distinct kinase
functions. As increasing the concentration of this PTK in-
creases differentiative activity but only modestly enhances
proliferative expansion, it seems unlikely that the defi-
ciency lies in a suboptimal level of kinase expression or ac-
tivity. Rather, based on these results we speculate that
FynT NH2-terminal domains may fail to efficiently couple
to downstream elements necessary to promote proliferative
expansion after pre-TCR triggering. Among these ele-
ments may be one or both of the secondary PTKs required
for this transition (ZAP-70 or Syk [10, 11]) and/or adaptor
molecules required to direct signals to specific downstream
signaling pathways (12, 13, 15, 17).
Interestingly, the proportion of thymocytes adopting the
CD4 or CD8 SP cell fate can be influenced by the dose and
structure of Src-PTKs expressed at DP to SP transition.
Thus, the propensity toward CD4 lineage development
that is characteristic of murine thymopoiesis is minimized
when PTKs lacking Lck NH2-terminal domains are used to
mediate signals at DP to SP transition (Fyn-lck). This find-
ing may reflect the fact that PTKs bearing Lck NH2-termi-
nal domains are required to facilitate the high level of sig-
naling necessary to promote adoption of the CD4 SP cell
fate, a view consistent with existing threshold models (17).
However, the finding that provision of additional Fyn ac-
tivity in the context of Fyn-lck appears to enhance CD8 SP
as opposed to CD4 SP development would seem inconsis-
tent with the concept that PTK activity by itself is the de-
termining factor driving the CD4 bias. A slightly modified
model incorporating our data would postulate that the Lck
NH2-terminal domains possess specialized features that en-
able efficient transduction of qualitatively distinct signals at
this transition. In this scenario, the Lck NH2 termini would
be more efficient than Fyn NH2 termini in engaging those
adaptors or mediators of downstream signaling pathways
that promote preferential CD4 SP development, such as el-
ements in the Ras/Raf/MEK/extracellular signal–regula-
tory kinase pathway (16, 17, 52, 61). Importantly, the shift
we observe in SP development toward the CD8 lineage
when Fyn expression is increased in Fyn-lckF:Lck2/2 mice,
a manipulation that would be expected to enhance signals
downstream of the TCR (18), further suggests that it is the
balance of signals generated via Fyn and Lck during selec-
tion that may direct progenitor commitment preferentially
toward CD8 versus CD4 SP lineages, respectively. This
notion would be consistent with recent findings indicating
that the extent of Lck participation during selection influ-
ences lineage commitment, and with current models link-
ing restricted signaling via the TCR to development of the
CD8 lineage (62). These unique combinations of signaling
events that reflect the relative participation of Lck and Fyn
during selection could then serve as preferential targets of
amplification or modification by other signaling pathways,
including Notch (63). In summary, our data support the
view that specific features of the Lck structure make this
member of the Src family uniquely suited to relay TCR-
dependent signals at both DN to DP and DP to SP check-
points. To gain a deeper understanding of Lck action at
these transitions, it will be necessary to identify the specific
PTK structures involved in conferring Lck potency, and
the downstream signaling pathways influenced by these
structures.
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